Cytek Biosciences, Inc.
CTKB
$4.81
$0.153.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 9.07% | -28.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.07% | -28.98% | |||
| Cost of Revenue | -1.23% | -21.79% | |||
| Gross Profit | 20.17% | -35.37% | |||
| SG&A Expenses | -0.38% | 2.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.41% | -7.58% | |||
| Operating Income | 23.09% | -230.05% | |||
| Income Before Tax | 32.98% | -330.98% | |||
| Income Tax Expenses | -65.51% | -96.27% | |||
| Earnings from Continuing Operations | 35.56% | 57.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.56% | 57.20% | |||
| EBIT | 23.09% | -230.05% | |||
| EBITDA | 26.55% | -348.84% | |||
| EPS Basic | 35.95% | 57.37% | |||
| Normalized Basic EPS | 26.54% | -328.43% | |||
| EPS Diluted | 37.40% | 56.38% | |||
| Normalized Diluted EPS | 26.54% | -328.43% | |||
| Average Basic Shares Outstanding | 0.59% | 0.42% | |||
| Average Diluted Shares Outstanding | 0.59% | 0.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||